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ImplIcatIons of the BG In sleep–wake control
The BG has been implicated in a variety of motor and  cognitive 
behaviors, including planning and other executive functions (Nambu, 
2008). While these “higher level” cognitive processes are associated 
with the vigilance state of wakefulness, the involvement of the BG 
in the control of wakefulness per se has received very little attention. 
The BG is very likely involved in sleep regulation, considering the 
occurrence and high prevalence of sleep-related issues in patients 
with BG-related neurogenerative disorders, such as Parkinson’s dis-
ease (PD) and Huntington’s disease (HD). Disturbances of sleep are 
highly prevalent in PD, affecting up to 88% of patients in a commu-
nity-based study (Factor et al., 1990), although a range of 55–98% 
has been reported across various studies (Larsen and Tandberg, 
2001; Kaynak et al., 2005; Gjerstad et al., 2007). However, the inter-
action between PD and sleep is complex because PD patients may 
also have primary sleep disturbances such as rapid eye movement 
(REM) sleep behavior disorder, periodic limb movements during 
sleep and restless legs syndrome (Askenasy, 2001). Other factors such 
as depression, reactions to medications, nocturia, akinesia, pain, and 
dystonia may also underlie their sleep disturbances (Dhawan et al., 
2006; Chaudhuri and Schapira, 2009). Nevertheless, insomnia and 
daytime sleepiness are the most frequent sleep-related complaints of 
PD patients. Although both sleep-onset insomnia and sleep-main-
tenance insomnia are reported in PD, sleep-maintenance insomnia 
is more common, affecting 74–88% of PD patients (Factor et al., 
1990). Moreover, polysomnographic studies have demonstrated that 
these patients experience light and fragmented sleep. Similar to PD 
patients, HD patients have also been found to spend less total time 
in slow wave sleep (SWS) and REM sleep and have fragmentation 
in all states of sleep–wakefulness (S–W). In the most severe cases of 
HD, REM sleep has been reported to be completely absent (Arnulf 
et al., 2008). In addition to these clinical findings suggesting the 
involvement of the BG in S–W, many preclinical studies in animal 
neurochemIstry of the Basal GanGlIa
The BG consists of four major nuclei, including the striatum (cau-
date and putamen), globus pallidus (GP), subthalamic nucleus 
(STN), and substantia nigra. Each of these nuclei differs in their 
neurochemistry, projection pattern, and function (see follow-
ing sections). More than 95% of neurons in the striatum are 
projection neurons while the remaining 5% are interneurons 
(Wichmann and DeLong, 2006; Kreitzer, 2009). The projec-
tion neurons, which are medium spiny neurons (MSN), contain 
gamma amino butyric acid (GABA) as their neurotransmitter and 
hence are inhibitory in nature (Wichmann and DeLong, 2006). 
Some of the interneurons in the striatum, on the other hand, 
are excitatory and contain acetylcholine as their neurotransmit-
ter (Lobo, 2009; Nambu, 2009). These cholinergic interneurons 
express vesicular glutamate transporter 3 (VGLUT3), and thus 
may also contain glutamate. The rest of the interneurons in the 
striatum are mostly GABAergic.
Although traditionally the GP is considered as a single nucleus, 
it comprises two neurochemically and functionally distinct sub-
nuclei – the globus pallidus external (GPe) and globus pallidus 
internal (GPi). All the neurons in the GPe are GABAergic whereas 
the GPi contains both glutamatergic and GABAergic neurons 
(Barroso-Chinea et al., 2008). It is likely that both GABA and 
glutamate are present in the same neurons in the GPi, but it has 
never been confirmed. STN neurons are also glutamatergic, while 
the substantia nigra pars compacta (SNc) and pars reticulata 
(SNr) comprise mostly dopaminergic and GABAergic neurons, 
respectively (Wichmann and DeLong, 2006). In addition to 
these major neurotransmitters, BG neurons also contain other 
transmitters or neuropeptides, including enkephalin (ENK) 
and dynorphin in striatal MSNs; substance P, neuropeptide Y 
and nitric oxide in the striatal interneurons; and ENK in the 
GPe neurons.
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To supplement the electrophysiological data, we used cFos as 
a marker for neuronal activity and studied cFos expression in the 
various nuclei of the BG during wake and sleep in rats. Animals 
were sacrificed either after spontaneous sleep (sleep group, n = 5), 
after 2 h of sleep deprivation (wake group, n = 5) or 2 h after 
intraperitoneal injection of methamphetamine (drug-induced 
wake group, n = 5) at a dose of 1 mg/kg body weight. The animals 
were sacrificed during the same circadian time to avoid any cir-
cadian influence in cFos expression. After perfusions, rat brains 
were sectioned at 40 μm into four series, and one series was immu-
nohistochemically dual-labeled for tyrosine hydroxylase (TH, a 
marker for dopaminergic neurons) and cFos. Our data (Figure 1) 
showed that cFos expression in the dorsal striatum and STN was 
elevated during wakefulness (immediately after sleep deprivation) 
and during active wakefulness following administration of meth-
amphetamine (1.0 mg/kg), compared to during sleep. The medial 
part of the GPe also showed a moderate increase in cFos expression 
during both types of wakefulness than during sleep. On the other 
hand, cFos expression in the ventral striatum (i.e., the nucleus of 
the accumbens), GPi and SNr was considerably lower during both 
wakefulness and sleep but slightly higher in the GPi and SNr during 
wakefulness (of both types) than during sleep. Finally, cFos expres-
sion was not observed in the dopaminergic neurons in the VTA, 
SNc and retrorubal area in any of these conditions. Collectively, 
these results suggest that cFos activity and neuronal firing patterns 
are distinct in different nuclei of the BG, and that they may play 
specific independent roles in S–W regulation. These differences in 
activity pattern can be partially explained by their differences in 
neurochemistry, and thus juxtacellular and dual immunolabeling 
studies are ultimately required for a better understanding of BG 
neuronal activity across S–W stages.
The effecTs of neuroToxic lesions in The BG on s–W
While the abovementioned electrophysiological and cFos studies 
provide evidence for the association of BG neuronal activity with 
the sleep–wake cycle, the lesion studies conducted in our lab and 
others’ established that the BG plays a significant causal role in S–W 
regulation. In order to study the specific roles played by different 
nuclei of the BG in S–W regulation, we placed small cell-specific 
lesions in the BG of rats using ibotenic acid (Qiu et al., 2010). 
As expected, we found dramatic changes in S–W amounts and 
architecture following discrete lesions of the various BG nuclei. 
Bilateral striatal lesions resulted in a significant reduction (ca. 15%) 
of wakefulness, and in fragmentation of both sleep and wakefulness. 
Sleep and wake bouts were shorter in general, but there were more 
frequent transitions, especially during the dark period in the ani-
mals with striatal lesions. Interestingly, this reduction in wakeful-
ness after striatal lesions was attenuated when the lesions included 
the nucleus of accumbens core (NAc) (Qiu et al., 2010), suggesting 
that the dorsal and ventral striatum may play opposing roles in 
S–W regulation. Consistent with this, lesions restricted to the NAc 
transiently produced an increase in wakefulness (Qiu et al., 2010). 
Thus, these results indicate an important role for the striatum in the 
maintenance of wakefulness, as the dorsal striatum is one of very 
few structures that produces an increase in sleep and fragmenta-
tion of wakefulness after cell-specific lesions. For example, lesions 
of many previously-established wake-promoting cell groups, 
models have shown that the BG may play an important role in S–W 
behavior and cortical activation, which will be the main focus of 
this review.
neuronal acTiviTy of The BG across s–W Behavior
Although the activity pattern of BG neurons has been studied 
extensively, only a few studies have investigated BG unit activity in 
relation to cortical EEG or the sleep–wake states. Nevertheless, the 
available studies indicate that most of the BG neurons are wake-
REM active, meaning they fire faster during wake and REM sleep 
(desynchronized EEG) than during SWS. For example, Mahon and 
colleagues performed intracellular recordings from striatal MSNs 
and showed that MSN activity critically depended upon the vigi-
lance state. MSNs exhibited rhythmic action potential fluctuations 
between a DOWN state (hyperpolarized quiescent state) and an 
UP state (depolarized state) during SWS, coincident with corti-
cal activity, but during wake and REM sleep they switched into 
high rates of discharge with “random” patterns that were not syn-
chronized with cortical EEG UP and DOWN states (Detari et al., 
1987; Mahon et al., 2003; Mahon et al., 2006). Similar to striatal 
MSNs, GPe neurons are more active during wake and REM sleep 
(Urbain et al., 2000). These findings from head-restrained animals 
were recently confirmed in our laboratory using freely-moving 
animals (S. Thankachan and J. Lu, unpublished data). This study 
demonstrated that ca. 50% of GPe neurons increased their firing 
during REM sleep and during active wakefulness. In addition, 
GPe neurons tend to display burst-firing regardless of S–W state. 
Moreover, it has been shown that GPe burst-firing is reduced fol-
lowing dopamine depletion in the BG in experimental animals and 
in PD patients (Pan and Walters, 1988; Filion and Tremblay, 1991; 
Filion et al., 1991; Hutchison et al., 1994; Bouali-Benazzouz et al., 
2009). Finally, while SNc dopaminergic neurons do not particu-
larly change their firing rates across S–W behavior, they switch to 
burst-firing mode during wake and REM sleep (Dahan et al., 2007; 
Monti and Monti, 2007). Burst-firing in the SNc may trigger more 
dopamine release in the BG during wake and REM sleep, and thus 
may have a stronger influence on striatal and GPe activity during 
wake and REM sleep than during SWS. Taken together, it appears 
that BG neuronal activity is lower during SWS than during wake 
or REM sleep, and depends upon cortical activity. In accordance 
with these conclusions, cortical stimulation triggered a sequence 
of postsynaptic responses including initially a short EPSP, then a 
short IPSP, and then a late EPSP with multiple spikes in all the BG 
nuclei including the striatum, GPe, GPi, STN, and SNr (Wilson 
et al., 1983; Kita, 1992; Fujimoto and Kita, 1993; Nambu et al., 
2000). However, considering the numerous excitatory and inhibi-
tory connections between the BG nuclei, it is not clear how corti-
cal stimulations elicit the same sequence of postsynaptic events 
in all these nuclei. It is possible that powerful cortical drives can 
overpower other within-BG synaptic events. It is also possible that 
the latency of these events could be different in different nuclei 
following cortical stimulation, as none of these studies recorded 
neuronal activity from the different BG nuclei simultaneously fol-
lowing cortical stimulation. Nevertheless, it is known that neuronal 
activity in all the BG nuclei is strongly synchronized with cortical 
activity and is modulated by dopamine, serotonin and thalamic 
inputs during wakefulness and REM sleep.
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and laterodorsal tegmental nuclei (Lu et al., 2006b) and orexin 
neurons in the lateral hypothalamus (Hara et al., 2001) did not 
produce an increase in sleep, although S–W fragmentation was 
observed after these lesions. Other nuclei that have been found to 
increase sleep following cell-specific lesions, similar to the dorsal 
 including the cholinergic basal forebrain (BF) neurons, seroton-
ergic dorsal raphe (DR) neurons, histaminergic tuberomammillary 
nucleus (Parmentier et al., 2002; Gerashchenko et al., 2004; Lu et al., 
2006a; Blanco-Centurion et al., 2007), noradrenergic locus coeru-
leus (Blanco-Centurion et al., 2007), cholinergic  pedunculopontine 
Figure 1 | cFos expression in the basal ganglia 2 h after 
methamphetamine (1.0 mg/kg) administration, after 2 h of wakefulness or 
during spontaneous sleep. Both waking states are associated with a higher 
number of cFos-labeled cells in the dorsal striatum, external globus pallidus 
(GPe), and subthalamic nucleus (STN) than the sleep state cFos expression in 
the internal globus pallidus (GPi) and substantia nigra pars reticulata (SNr) is low 
in all three conditions and indistinguishable between wakefulness and sleep. On 
the other hand, dopamine neurons in the ventral tegmental area (VTA), 
substantia nigra pars compacta (SNc) and the retrorubal area do not express 
cFos in any of these states.
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brain and/or caudal hypothalamus, which may cause hypersomnia 
but not insomnia (Castaigne et al., 1981; Hermann et al., 2008). As 
mentioned earlier, rats with GPe lesions show behavioral changes 
that match the symptoms of FFI including insomnia, weight loss and 
abnormal motor behavior and these rats often die within 3–4 weeks. 
So, we hypothesize that pathology in the GPe may be the underlying 
cause of FFI. Consistent with this, hypometabolism in the BG has 
been reported in FFI patients (Cortelli et al., 1997).
 In contrast to striatal and GPe lesions, ibotenic acid lesions in 
the GPi, STN or SNr did not significantly alter S–W, despite their 
close interactions with the striatum and GPe (Qiu et al., 2010). 
Furthermore, extensive lesions of the thalamus do not significantly 
affect S–W and motor behavior (Vanderwolf and Stewart, 1988). 
These results suggest that the integrity of the GPi, STN, SNr, and 
even thalamus may not be critical for the generation and main-
tenance of S–W states, although they may modulate S–W. These 
findings provide a basis on which a putative network for the BG 
control of S–W may be framed.
proposed BG cIrcuItry controllInG s–w BehavIor
Neuroanatomical connections between the BG and cerebral 
cortex are complex and characterized by many recurrent cir-
cuits (Figure 2A). On the basis of our lesion and cFos stud-
ies, we hypothesize that the recurrent interactions between 
the BG and cerebral cortex may influence cortical arousal and 
S–W behavior. Overall, there are five potential neural pathways 
that connect the BG and cortex: cortex-striatum-GPe-cortex; 
cortex-STN-GPe- cortex; cortex-STN-GPe-thalamus-cortex; 
cortex-striatum-GPe-GPi/SNr-thalamus-cortex; and cortex-
striatum-GPe-thalamus-cortex (Figure 2A). The GPi and SNr 
have descending projections to the intermediate layer of the supe-
rior colliculus and midbrain extrapyramidal area (MEA), but not 
to the cholinergic neurons in the pedunculopontine tegmentum 
nucleus (PPT) (Rye et al., 1987; Steininger et al., 1992). The MEA 
targets the spinal-projecting neurons of the midbrain locomotor 
region (MLR) involved in the regulation of motor behavior (D. 
Sherman and J. Lu, unpublished data). Thus, this circuit may be 
involved in the BG control of posture and locomotion, but not 
of S–W regulation. The lack of sleep changes following lesions of 
the GPi and SNr further confirms this hypothesis. On the other 
hand, there are two structures within the BG-cortex pathways 
that contain direct cortical-projecting neurons: the GPe and the 
thalamus. As it has been shown that thalamic lesions do not have 
any significant effect on S–W, we can confine the key S–W control 
circuit of the BG to the striato-pallido-cortical loop (highlighted 
by black lines in Figure 2A). In this framework, the striatum-
GPe-cortex loop may relay and enhance cortical arousal signals 
and thereby regulate wakefulness. This loop may also enhance 
and stabilize the excitatory state of the pyramidal neurons, i.e., 
cortical activation, which is consistent with the spectral changes 
in EEG recordings following lesions of the striatum and GPe. 
Lesions in both the striatum and GPe caused a significant shift in 
EEG power from the theta to the delta range during wake, NREM 
sleep and REM sleep, indicating that lesions in the BG resulted 
in a slowing down of the cortical EEG. Thus, we can conclude 
that the BG are involved in regulating the level of electrocortical 
arousal as well as behavioral arousal.
striatum, are the medial parabrachial nucleus, the lateral hypotha-
lamus and the dopaminergic ventral periaquaductal gray matter 
(vPAG) (Gerashchenko et al., 2003; Lu et al., 2006a,b).
 Conversely, lesions of the GPe resulted in profound insom-
nia in rats with a striking 45.5% increase in total wakefulness and 
pronounced fragmentation of sleep and wakefulness. These S–W 
changes are comparable to the lesion effects produced by the only 
established sleep-promoting cell group, the ventrolateral preoptic 
area (VLPO), and thus suggest that the GPe may be another key 
player in the S–W control mechanism. In addition to the S–W 
changes, GPe lesions also produced hyperactivity and weight loss 
in rats. Although we were the first to report sleep changes after GPe 
lesions, hyperactivity and weight loss have been observed previously. 
We hypothesize that the weight loss following GPe lesions may be 
due to an oral motor disorder, based on our observations during the 
initial stimulatory phase of ibotenic acid injections. Since ibotenic 
acid is a glutamate agonist, it has a strong excitatory effect immedi-
ately following the injection (acute phase) before causing neuronal 
cell death. We observed capricious chewing behavior lasting over 
24 h following ibotenic acid injections, and this chewing behavior 
did not result in food intake even in the presence of food. Following 
this acute phase, animals stopped eating and drinking and started 
losing weight abruptly. Similar effects were observed after electro-
lytic lesions of the lateral hypothalamus, which damages both the 
cell bodies and the fibers of passage, and were collectively recog-
nized as lateral hypothalamic syndrome (Rowland and Stricker, 
1982). 6-hydroxydopamine (6-OHDA) injections into the lateral 
hypothalamus that eliminate dopaminergic inputs to the striatum 
and GPe produced a similar reduction in body weight (Lenard et al., 
1988). Finally, aphagia, adipsia and weight loss were observed in 
mice with dopamine deficiency, and these symptoms were corrected 
by daily administration of l-DOPA (Zhou and Palmiter, 1995). 
Altogether, these results strongly suggest that dopaminergic inputs 
to the GPe may play a key role in controlling oral motor behavior, 
thus affecting food/water intake. In light of these findings, it is 
interesting to note that PD patients, particularly in the advanced 
stages, also have difficulty controlling their oral motor muscles and 
thus have difficulty swallowing, drinking and displaying normal 
facial expressions. In addition to these oral motor problems, rats 
with GPe lesions showed other abnormal motor behaviors such 
as long bouts of standing and a scuffling locomotion. However, 
unlike S–W alterations, these motor disorders seem compensated 
for within 2 weeks.
In addition, we speculate that the effects of GPe lesions may 
mimic the symptoms of fatal familial insomnia (FFI), an autosomal 
dominant inherited neurodegenerative disease caused by a prions 
(PrC, a disease-associated prion protein) (Montagna et al., 2003). 
Patients with FFI exhibit total insomnia, autonomic dysregulation, 
rapid weight loss, abnormal motor behaviors and dementia, and die 
within months of disease onset. Brain autopsies showed extensive 
neuronal lesions, particularly in the thalamus and brainstem, and 
it is widely believed that the thalamic lesions underlie the insomnia 
in FFI (Perani et al., 1993). However, discrete neurotoxic lesions in 
the thalamus do not produce significant changes in the S–W cycle, 
motor behavior or body weight in rats (Vanderwolf and Stewart, 
1988). Furthermore, infarctions in FFI patients are rarely confined to 
the bilateral thalamus, and thalamic strokes often include the mid-
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On the basis of these results, we hypothesized the possible mech-
anism by which the GPe contributes to S–W behavior and cortical 
activity. Our view is that corticopetal GABAergic GPe neurons act 
to suppress cortical activity regardless of S–W state and synchronize 
the fast cortical oscillations by targeting layer V pyramidal neu-
rons and GABAergic interneurons (Figure 4). Once this inhibition 
is reduced (such as by the loss of dopamine inputs) or removed 
(such as in cell-body lesions), the layer V pyramidal neurons in 
the cerebral cortex, including the motor cortex, may switch to a 
more depolarized state as occurs during the wake state. This model 
is consistent with the observation that both lesions in the GPe 
and SNc (the source of dopaminergic neurons to the BG) increase 
wakefulness. This hypothesis is further supported by the finding 
that EEG delta power is increased and theta power is reduced after 
GPe lesions (Qiu et al., 2010), and that the EEG waves are slower 
in PD patients where dopamine inputs to the BG are lost (Soikkeli 
et al., 1991; Serizawa et al., 2008; Morita et al., 2009). Hence, it can 
be concluded that the GPe may be one of the many cell groups, 
including the basal forebrain, thalamus, lateral hypothalamus, LC, 
and VTA, that directly modulate cortical activity.
how does mIdBraIn dopamIne modulate thIs cIrcuIt?
It is well-established that the loss of dopamine inputs to the BG 
produces PD, and insomnia is highly prevalent among PD patients. 
The major source of dopamine in the BG is the midbrain dopamin-
ergic neurons, particularly the SNc (A9 group), and these neurons 
primarily target the striatum, GPe and GPi. Neurotoxic lesions of 
the SNc in animals using 6-OHDA or NMDA agonists produced 
an increase in wakefulness (Lai et al., 1999; Sakata et al., 2002; 
Gerashchenko et al., 2006), suggesting that nigral dopaminergic 
inputs to the BG may promote sleep and the loss of dopaminergic 
inputs to the BG may underlie insomnia in PD patients. Moreover, 
As mentioned previously, the GPe contains direct cortical-
projecting neurons (Gritti et al., 1997; Sarter and Bruno, 2002; 
Furuta et al., 2004; Hur and Zaborszky, 2005). These pallidocortical 
projections have not been well-recognized mostly because they 
were previously assumed to be the part of the BF cortical projec-
tions. However, the BF cholinergic neurons (Nucleus Basalis of 
Mynert) located along the medial and ventral borders of the GPe 
seem to be distinct from the GABAergic corticopetal neurons within 
the GPe. This was supported by the finding that non-cholinergic, 
GABAergic neurons in the GPe (well within the boundaries) send 
ascending projections to the cortex (Gritti et al., 1997; Sarter and 
Bruno, 2002; Furuta et al., 2004). Interestingly, similar to the BF 
cortical projections, pallidocortical projections may be topographi-
cal. For example, the medial part of the GPe projects to the mPFC 
(Figure 3), while other parts of the GPe project to the insular, 
motor, and sensory cortices (Saper, 1984). In order to identify the 
GPe target neurons in the cortex, we injected a cocktail of tracers 
containing a retrograde tracer, cholera toxin subunit B (CTB), and 
an anterograde tracer, biotinylated dextranamide (BD), into the 
GPe into two rats. One week after the injections, these rats were 
sacrificed and the brains were harvested and processed for immu-
nohistochemical identification of BD, CTB, and GAD 67. We found 
that most of the BD-labeled axon terminals (anterogradely labeled 
from the GPe) were in cortical layers IV-V (Figure 4C), where they 
formed appositions with CTB-immunoreactive (CTB-ir) neurons 
(Figure 4) and GAD 67-ir neurons. These CTB-ir neurons were 
pyramidal neurons and are presumably glutamatergic. Thus, these 
results suggest that GPe neurons target both GABAergic interneu-
rons and glutamatergic pyramidal neurons in the cortex, and that 
these two regions are reciprocally connected. Projections to layer 
V are particularly important, as this layer is critical for generating 
EEG waves (Sanchez-Vives and McCormick, 2000).
Figure 2 | The basal ganglia network (A) and extra-basal ganglia network (B) 
hypothesized to be involved in sleep–wake control mechanisms. Several 
pathways connect the basal ganglia with the cerebral cortex, including the 
cortex-thalamus-striatum-cortex pathway, the cortex-striatum-GPe-cortex 
pathway, the cortex-STN-GPe-cortex and others. Of these pathways, our data 
indicate that the cortex-striatum-GPe-cortex network, marked by the black lines 
[in (A)], is involved in the control of sleep–wake behavior and cortical activation. 
By activating the D2 receptors in this network, dopamine from the midbrain 
disinhibits the GPe and promotes sleep. On the other hand, wake-active 
dopaminergic neurons in the vPAG promote wakefulness by inhibiting the 
sleep-promoting neurons in the VLPO and stimulating the wake-promoting cell 
groups, including the LH orexin neurons, PPT/LDT cholinergic neurons, PB/PC 
glutamatergic neurons and BF cholinergic neurons (B). Thus, the collective 
actions of dopamine in the extra-basal ganglia circuitry promote wakefulness. 
This network may also be responsible for the arousal effects of 
psychostimulants. BF, basal forebrain; vPAG, ventral periaquductal gray; PPT, 
pedunculopontine tegmental nucleus; LH, lateral hypothalamus; LDT, 
laterodorsal tegmental nucleus; PB, parabrachial nucleus; PC, precoeruleus 
nucleus; DA, dopamine; VLPO, ventrolateral preoptic nucleus. Arrows 
represents excitatory synapses; roundheads represent inhibitory synapses. The 
bars with both symbols represent the reciprocal connection between these 
nuclei with excitatory and/or inhibitory synapses on the target structure.
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Figure 3 | Pallidocortical projections. A mixture of a retrograde tracer 
(cholera toxin subunit B, CTB) and an anterograde tracer (biotin dextranamide, 
BD) were injected into the medial prefrontal cortex (mPFC) of rats to assess 
the pallidocortical projections. The injection site in the mPFC (A) was identified 
by CTB + BD immunolabeling. A large number of retrogradely-labeled 
(CTB-immunoreactive) neurons were found in the medial part of the GPe (B) 
and the same region also contained anterogradely labeled (BD-
immunoreactive) neuron terminals (B,C), indicating that the GPe and mPFC 
are reciprocally connected. The boxed region in (B) is enlarged in (C), and 
arrows in (C) indicate the CTB-ir neurons in the GPe. ACC, anterior cingulate 
cortex; PL, prelimbic cortex; IF, infralimbic cortex; ic, internal capsule; BST, bed 
nucleus of stria terminalis.
Figure 4 | The external globus pallidus (gPe) targets both gABAergic 
and non-gABAergic neurons in the cortex. A mixture of a retrograde 
tracer (cholera toxin subunit B, CTB) and an anterograde tracer (biotin 
dextranamide, BD) was injected into the GPe (A) in a rat to characterize 
the target neurons of pallidal projections to the cortex. Brain sections were 
immunolabelled for BD, CTB, and glutamic acid decarboxylase (GAD 67). 
(A) Shows the injection site in the GPe. Anterogradely-labeled (BD-ir) axon 
terminals were mostly present in layers IV and V of the M2 and anterior 
cingulate cortices (B,C), where a high number of retrogradely-labeled (CTB-ir) 
cells were present (B). The boxed region in (C) is enlarged in (D). The BD-
labeled boutons appose both the GABAergic neurons (green and black arrows) 
and glutamatergic pyramidal neurons (red and black arrows) in the cortex 
(D). Black arrows mark the axon terminal boutons; CTB-labeled neurons are 
stained in black color (red arrows) and GABAergic neurons are stained in 
brown color (green arrows). M1, primary motor cortex; M2, secondary 
motor cortex.
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1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated 
animals, one of the best-known animal models of PD, displayed a 
significant reduction in the amount of SWS (Almirall et al., 1999; 
Monaca et al., 2004). Although it is believed that MPTP may damage 
noradrenergic and serotonergic cells in addition to dopaminergic 
neurons, sleep loss in the MPTP-treated animals seems to be pri-
marily caused by the loss of nigrostriatal dopaminergic neurons. 
The reasons for this claim are several fold: (1) noradrenergic LC 
and serotonergic DR neurons have been implicated in promoting 
wakefulness, hence damage to these neurons would be expected 
to produce an increase in sleep rather than wakefulness. However, 
specific neurotoxic lesions of the LC or DR did not affect spontane-
ous sleep in rats (Lu et al., 2006b). (2) MPTP-induced insomnia 
cannot be attributed to extra-BG dopaminergic systems, includ-
ing the VTA and vPAG, because VTA neurons have been shown to 
be protective against MPTP toxicity and VTA lesions do not alter 
S–W. On the other hand, vPAG lesions produced an increase in 
sleep, although vPAG neurons’ vulnerability to MPTP is not known. 
These findings clearly suggest that sleep loss observed after MPTP-
lesions in animals may due to the loss of nigrostriatal dopaminergic 
neurons, and thus indicate that dopamine signaling in the BG may 
be involved in promoting sleep.
 The view that endogenous dopamine in the BG promotes 
sleep appears contradictory to the popular view that dopamine 
may be important for wakefulness and arousal. However, it is well-
known that low doses of apomorphine (100 μg/kg), a mixed D1/D2 
dopamine receptor agonist, and l-DOPA induce sleep in animals 
and humans and trigger sleep attacks in PD patients, even during 
high arousal states such as when driving. However, high doses of 
apomorphine and l-DOPA induce arousal (Schafer and Greulich, 
2000; Bonuccelli et al., 2002; Dimpfel, 2008; Hirayama et al., 2008; 
Garcia Ruiz, 2009). A D2 receptor antagonist has been shown to 
block the sleep-inducing effects of apomorphine, while a D1 recep-
tor antagonist blocked the arousal effects (Gessa et al., 1985). In 
addition, systemic injections of a selective D1 agonist resulted in 
desynchronization of the EEG and an increase in wakefulness, 
whereas D1 antagonists produced a dose-dependent increase in 
sleep in mammals. Even in humans, a novel D1 receptor antagonist, 
NNC-687, increased the length of the first NREM period up to 
47% over baseline and enhanced the total number, incidence, and 
burst-duration of sleep spindles. These evidences collectively indi-
cate that activation of the D1 receptors may promote wakefulness 
and activation of the D2 receptors may promote sleep, although 
their specific site of action is not clear. On the basis of the current 
literature and our results, we hypothesize that activation of the 
D2 receptors in the BG promote sleep while activation of the D1 
receptors in the extra-BG sites promote wakefulness, though these 
actions may not be exclusive.
 Dopamine may act on presynaptic or postsynaptic dopamin-
ergic receptors to bring about its effect on the target tissues. D1 
and D2 dopaminergic receptors are abundantly expressed in the 
cerebral cortex while D1, D2, D3, and D5 receptors are expressed 
in the striatum and D2, D3, and D5 receptors are expressed in the 
GPe. Within the striatum, dopamine may exert its actions on the 
striatonigral neurons via D1 receptors, on striatopallidal neurons 
via D2 receptors, and on cholinergic interneurons via D5 recep-
tors (Rivera et al., 2002). The D2 receptors are found to be located 
presynaptically on striatopallidal GABAergic terminals in the GPe, 
although dopamine may also exert its actions on GPe and GPi 
neurons via postsynaptic D2 receptors. Most GPe neurons have 
been shown to fire more slowly and in a bursting pattern following 
the loss of dopamine inputs, suggesting that the loss of dopamine 
inputs results in hypoactivity of the GPe neurons. Hence, it is likely 
that dopamine primarily acts on postsynaptic D2 receptors in the 
striatum and presynaptic D2 receptors in the GPe to bring about 
its effects on GPe neurons (Cooper and Stanford, 2001; Querejeta 
et al., 2001). It can therefore be inferred that the loss of D2 postsy-
naptic and presynaptic inhibition in the striatum and GPe would 
result in hyperactivity of the striatopallidal neurons, resulting in 
inhibition (presumably GABA-mediated) of the GPe neurons, 
which would then result in increased arousal. We thus hypothesized 
that endogenous dopamine in the BG promotes sleep by acting on 
the D2 receptors in the striatopallidal neurons. However, it was 
found that D2 receptor global knockout mice are hyperactive but 
show a significant reduction in wakefulness (Qu et al., 2010). Due 
to the wide distribution of D2 receptors in the brain, it has not 
been possible to identify the site where D2 receptor activation may 
promote wakefulness and where their absence in the D2 knockout 
mice may reduce wakefulness. Since our model predicts that the loss 
of D2 receptors in the BG may result in an increase in wakefulness, 
the reduced wakefulness in D2 knockout mice may be due to the 
absence of functional D2 receptors in the extra-BG sites, such as 
the cerebral cortex, BF, LH, and other wake-promoting cell groups 
in the brainstem and caudal hypothalamus (Figure 2B).
The VTA was thought to be such an extra-BG dopaminergic 
system involved in promoting wakefulness because it has direct 
projections to the prefrontal cortex. In line with this hypothesis, 
microinjection of apomorphine (D2 agonist) into the VTA pro-
duced a dose-dependent increase in behavioral and EEG sleep in 
rats, suggesting that VTA dopaminergic neurons may promote 
wakefulness, and D2-mediated inhibition of these neurons may 
promote sleep. However, these results are hard to reconcile with 
the findings that NMDA-induced VTA lesions in cats produced an 
increase in wakefulness rather than an increase in sleep, and orexin-
saporin lesions of the VTA in rats did not produce any change in 
S–W. Although the loss of non-dopaminergic neurons in the VTA 
(which may play an opposing role in sleep regulation) cannot be 
overruled in these studies, we recently found that selective lesions 
of VTA dopaminergic neurons using 6-OHDA also did not produce 
an increase in sleep in rats (R. Vetrivelan and J. Lu, unpublished 
observations). Moreover, VTA neuronal firing rate and cFos expres-
sion (Figure 1) did not differ significantly across S–W states. Hence, 
the role of VTA dopaminergic neurons in promoting wakefulness 
is inconclusive.
However, we recently identified a novel dopaminergic cell group, 
the vPAG (Lu et al., 2006a), which may be critically involved in the 
promotion and maintenance of wakefulness. Unlike the VTA, a 
variety of experimental approaches confirmed the vPAG neurons 
as being a wake-promoting cell group. For example, vPAG neu-
rons express cFos during wakefulness, and selective cell-specific 
lesions of the vPAG produced a significant (ca. 20%) reduction 
in wakefulness (Lu et al., 2006a). In addition, the vPAG is recipro-
cally connected with all the major components of the sleep–wake 
circuitry, including the sleep-promoting cell group, the VLPO, and 
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mice (Wisor et al., 2001). In contrast, animals with SNc lesions 
are paradoxically  supersensitive to the arousal and motor effects of 
 methamphetamine or amphetamine (Mandel and Randall, 1985; 
Schroeder et al., 1997, M. Qiu and J. Lu, unpublished observations). 
Previously, up-regulation of dopamine receptors in the BG had 
been proposed to be a potential mechanism of methamphetamine 
supersensitivity. However, this explanation is hard to reconcile with 
the fact that there is a very low level of dopamine in the BG after 
elimination of the SNc – the main dopamine source of the BG. 
Therefore, we hypothesize that methamphetamine supersensitiv-
ity may be due to the additive effects of (1) increased wakefulness 
following the loss of dopamine inputs to the BG and (2) increased 
wakefulness due to excess dopamine in the extra-BG sites following 
methamphetamine administration.
conclusIons
Research during the last decade has provided important insights 
into the BG circuitry controlling S–W behavior, and how dopamine 
may modulate this circuit. Electrophysiological, cFos and lesion 
studies point to a distinct role for the individual BG nuclei in the 
regulation of S–W, and also suggest that dopamine plays oppos-
ing roles in the BG and extra-BG networks. We hypothesize that 
dopamine in the BG may promote sleep via D2 receptors, while 
the extra-BG vPAG dopaminergic system may promote wakeful-
ness via D1 and D2 receptors. Further studies using novel genetic 
methods are required to confirm this hypothesis. Developing a bet-
ter understanding of the role of dopamine in S–W may shed light 
on the neurochemical mechanisms underlying sleep disturbances 
observed in patients with PD or HD, which in turn will aid in the 
development of novel treatment options.
acknowledGments
This work was supported by US National Institutes of Health grants 
– NS062727, NS061842, and NS051609 to Jun Lu; Ramalingam 
Vetrivelan is the recipient of a Pilot and Feasibility Award from the 
US National Institutes of Health-funded Boston Obesity Nutrition 
Research Center (P30 DK046200-17S1).
with the wake-promoting cell groups, including the BF, orexinergic 
 neurons in the lateral hypothalamus, and brainstem cholinergic 
(LDT) and monoaminergic (LC, DR, and median raphe) nuclei. 
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and D2 receptors extensively, the vPAG may activate (via D1) or 
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other hand, the vPAG dopaminergic neurons may inhibit the 
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(Fig 2B) and thus increasing wakefulness. Consistent with this 
hypothesis, DAT knockout mice did not display hyperactivity 
and arousal after administration of methamphetamine, although 
their spontaneous wakefulness was higher than that of intact 
Frontiers in Neuroanatomy www.frontiersin.org November 2010 | Volume 4 | Article 145 | 9
Vetrivelan et al. Basal ganglia and sleep
of globus pallidus neurons after the 
degeneration of nigrostriatal path-
way are mediated by the subthalamic 
nucleus in the rat. Eur. J. Neurosci. 12, 
4338–4344.
Pan, H. S., and Walters, J. R. (1988). 
Unilateral lesion of the nigrostriatal 
pathway decreases the firing rate and 
alters the firing pattern of globus pal-
lidus neurons in the rat. Synapse 2, 
650–656.
Parmentier, R., Ohtsu, H., Djebbara-
Hannas, Z., Valatx, J. L., Watanabe, 
T., and Lin, J. S. (2002). Anatomical, 
physiological, and pharmacological 
characteristics of histidine decarboxy-
lase knock-out mice: evidence for the 
role of brain histamine in behavioral 
and sleep-wake control. J. Neurosci. 22, 
7695–7711.
Perani, D., Cortelli, P., Lucignani, G., 
Montagna, P., Tinuper, P., Gallassi, R., 
Gambetti, P., Lenzi, G. L., Lugaresi, E., 
and Fazio, F. (1993). [18F]FDG PET in 
fatal familial insomnia: the functional 
effects of thalamic lesions. Neurology 
43, 2565–2569.
Qiu, M. H., Vetrivelan, R., Fuller, P. M., and 
Lu, J. (2010). Basal ganglia control of 
sleep-wake behavior and cortical acti-
vation. Eur. J. Neurosci. 31, 499–507.
Qu, W. M., Xu, X. H., Yan, M. M., Wang, 
Y. Q., Urade, Y., and Huang, Z. L. 
(2010). Essential role of dopamine 
D2 receptor in the maintenance of 
wakefulness, but not in homeostatic 
regulation of sleep, in mice. J. Neurosci. 
30, 4382–4389.
Querejeta, E., Delgado, A., Valdiosera, 
R., Erlij, D., and Aceves, J. (2001). 
Intrapallidal D2 dopamine receptors 
control globus pallidus neuron activity 
in the rat. Neurosci. Lett. 300, 79–82.
Rivera, A., Alberti, I., Martin, A. B., 
Narvaez, J. A., de la Calle, A., and 
Moratalla, R. (2002). Molecular phe-
notype of rat striatal neurons express-
ing the dopamine D5 receptor subtype. 
Eur. J. Neurosci. 16, 2049–2058.
Rowland, N., and Stricker, E. M. (1982). 
Effects of dopamine-depleting brain 
lesions on experimental hyperphagia 
in rats. Physiol. Behav. 28, 271–277.
Rye, D. B., Saper, C. B., Lee, H. J., and Wainer, 
B. H. (1987). Pedunculopontine teg-
mental nucleus of the rat: cytoar-
chitecture, cytochemistry, and some 
extrapyramidal connections of the 
mesopontine tegmentum. J. Comp. 
Neurol. 259, 483–528.
Sakata, M., Sei, H., Toida, K., Fujihara, 
H., Urushihara, R., and Morita, Y. 
(2002). Mesolimbic dopaminergic 
system is involved in diurnal blood 
pressure regulation. Brain Res. 928, 
194–201.
Sanchez-Vives, M. V., and McCormick, 
D. A. (2000). Cellular and network 
mechanisms of rhythmic recurrent 
hypothalamic feeding mechanisms: 
iontophoretic effects of kainic acid, 
ibotenic acid and 6-hydroxydopamine. 
Brain Res. Bull. 20, 847–856.
Lobo, M. K. (2009). Molecular profiling 
of striatonigral and striatopallidal 
medium spiny neurons past, present, 
and future. Int. Rev. Neurobiol. 89, 
1–35.
Lu, J., Jhou, T. C., and Saper, C. B. 
(2006a). Identification of wake-
active dopaminergic neurons in the 
ventral periaqueductal gray matter. J. 
Neurosci. 26, 193–202.
Lu, J., Sherman, D., Devor, M., and 
Saper, C. B. (2006b). A putative flip-
flop switch for control of REM sleep. 
Nature 441, 589–594.
Mahon, S., Deniau, J. M., and Charpier, 
S. (2003). Various synaptic activities 
and firing patterns in cortico-striatal 
and striatal neurons in vivo. J. Physiol. 
Paris 97, 557–566.
Mahon, S., Vautrelle, N., Pezard, L., Slaght, 
S. J., Deniau, J. M., Chouvet, G., and 
Charpier, S. (2006). Distinct patterns 
of striatal medium spiny neuron activ-
ity during the natural sleep-wake cycle. 
J. Neurosci. 26, 12587–12595.
Mandel, R. J., and Randall, P. K. (1985). 
Quantification of lesion-induced 
dopaminergic supersensitivity using 
the rotational model in the mouse. 
Brain Res. 330, 358–363.
Monaca, C., Laloux, C., Jacquesson, J. 
M., Gelé, P., Maréchal, X., Bordet, R., 
Destée, A., and Derambure, P. (2004). 
Vigilance states in a parkinsonian 
model, the MPTP mouse. Eur. J. 
Neurosci. 20, 2474–2478.
Montagna, P., Gambetti, P., Cortelli, P., 
and Lugaresi, E. (2003). Familial and 
sporadic fatal insomnia. Lancet Neurol. 
2, 167–176.
Monti, J. M., and Monti, D. (2007). The 
involvement of dopamine in the mod-
ulation of sleep and waking. Sleep Med. 
Rev. 11, 113–133.
Morita, A., Kamei, S., Serizawa, K., and 
Mizutani, T. (2009). The relationship 
between slowing EEGs and the pro-
gression of Parkinson’s disease. J. Clin. 
Neurophysiol. 26, 426–429.
Nambu, A. (2008). Seven problems on the 
basal ganglia. Curr. Opin. Neurobiol. 
18, 595–604.
Nambu, A. (2009). Functions of direct, 
indirect and hyperdirect pathways. 
Brain Nerve 61, 360–372.
Nambu, A., Tokuno, H., Hamada, I., 
Kita, H., Imanishi, M., Akazawa, T., 
Ikeuchi, Y., and Hasegawa, N. (2000). 
Excitatory cortical inputs to pallidal 
neurons via the subthalamic nucleus 
in the monkey. J. Neurophysiol. 84, 
289–300.
Ni, Z., Bouali-Benazzouz, R., Gao, D., 
Benabid, A. L., and Benazzouz, A. 
(2000). Changes in the firing pattern 
Insomnia in Parkinson’s disease: 
 frequency and progression over time. 
J. Neurol. Neurosurg. Psychiatr. 78, 
476–479.
Gritti, I., Mainville, L., Mancia, M., and 
Jones, B. E. (1997). GABAergic and 
other non-cholinergic basal forebrain 
neurons, together with cholinergic 
neurons, project to the mesocortex 
and isocortex in the rat. J. Comp. 
Neurol. 383, 163–177.
Hara, J., Beuckmann, C. T., Nambu, T., 
Willie, J. T., Chemelli, R. M., Sinton, 
C. M., Sugiyama, F., Yagami, K., Goto, 
K., Yanagisawa, M., and Sakurai, T. 
(2001). Genetic ablation of orexin 
neurons in mice results in narcolepsy, 
hypophagia, and obesity. Neuron 30, 
345–354.
Hermann, D. M., Siccoli, M., Brugger, P., 
Wachter, K., Mathis, J., Achermann, P., 
and Bassetti, C. L. (2008). Evolution 
of neurological, neuropsychological 
and sleep-wake disturbances after 
paramedian thalamic stroke. Stroke 
39, 62–68.
Hirayama, M., Nakamura, T., Hori, 
N., Koike, Y., and Sobue, G. (2008). 
The video images of sleep attacks in 
Parkinson’s disease. Mov. Disord. 23, 
288–290.
Hur, E. E., and Zaborszky, L. (2005). 
Vglut2 afferents to the medial prefron-
tal and primary somatosensory corti-
ces: a combined retrograde tracing in 
situ hybridization study [corrected]. J. 
Comp. Neurol. 483, 351–373.
Hutchison, W. D., Lozano, A. M., Davis, 
K. D., Saint-Cyr, J. A., Lang, A. E., and 
Dostrovsky, J. O. (1994). Differential 
neuronal activity in segments of glo-
bus pallidus in Parkinson’s disease 
patients. Neuroreport 5, 1533–1537.
Kaynak, D., Kiziltan, G., Kaynak, H., 
Benbir, G., and Uysal, O. (2005). 
Sleep and sleepiness in patients with 
Parkinson’s disease before and after 
dopaminergic treatment. Eur. J. 
Neurol. 12, 199–207.
Kita, H. (1992). Responses of globus pal-
lidus neurons to cortical stimulation: 
intracellular study in the rat. Brain Res. 
589, 84–90.
Kreitzer, A. C. (2009). Physiology and 
pharmacology of striatal neurons. 
Annu. Rev. Neurosci. 32, 127–147.
Lai, Y. Y., Shalita, T., Hajnik, T., Wu, J. P., 
Kuo, J. S., Chia, L. G., and Siegel, J. 
M. (1999). Neurotoxic N-methyl-D-
aspartate lesion of the ventral mid-
brain and mesopontine junction alters 
sleep-wake organization. Neuroscience 
90, 469–483.
Larsen, J. P., and Tandberg, E. (2001). Sleep 
disorders in patients with Parkinson’s 
disease: epidemiology and manage-
ment. CNS Drugs 15, 267–275.
Lenard, L., Jando, G., Karadi, Z., Hajnal, 
A., and Sandor, P. (1988). Lateral 
Dimpfel, W. (2008). Pharmacological 
modulation of dopaminergic brain 
activity and its reflection in spectral 
frequencies of the rat electrophar-
macogram. Neuropsychobiology 58, 
178–186.
Factor, S. A., McAlarney, T., Sanchez-
Ramos, J. R., and Weiner, W. J. (1990). 
Sleep disorders and sleep effect in 
Parkinson’s disease. Mov. Disord. 5, 
280–285.
Filion, M., and Tremblay, L. (1991). 
Abnormal spontaneous activity of 
globus pallidus neurons in monkeys 
with MPTP-induced parkinsonism. 
Brain Res. 547, 142–151.
Filion, M., Tremblay, L., and Bedard, P. J. 
(1991). Effects of dopamine agonists 
on the spontaneous activity of globus 
pallidus neurons in monkeys with 
MPTP-induced parkinsonism. Brain 
Res. 547, 152–161.
Fujimoto, K., and Kita, H. (1993). 
Response characteristics of subtha-
lamic neurons to the stimulation of 
the sensorimotor cortex in the rat. 
Brain Res. 609, 185–192.
Furuta, T., Koyano, K., Tomioka, R., 
Yanagawa, Y., and Kaneko, T. (2004). 
GABAergic basal forebrain neurons 
that express receptor for neurokinin B 
and send axons to the cerebral cortex. 
J. Comp. Neurol. 473, 43–58.
Gallopin, T., Luppi, P. H., Rambert, F. 
A., Frydman, A., and Fort, P. (2004). 
Effect of the wake-promoting agent 
modafinil on sleep-promoting neu-
rons from the ventrolateral preoptic 
nucleus: an in vitro pharmacologic 
study. Sleep 27, 19–25.
Garcia Ruiz, P. J. (2009). Sleep attack 
associated to rotigotine. Clin. 
Neuropharmacol. 32, 365.
Gerashchenko, D., Blanco-Centurion, 
C., Greco, M. A., and Shiromani, P. J. 
(2003). Effects of lateral hypothalamic 
lesion with the neurotoxin hypocretin-
2-saporin on sleep in Long-Evans rats. 
Neuroscience 116, 223–235.
Gerashchenko, D., Blanco-Centurion, C. 
A., Miller, J. D., and Shiromani, P. J. 
(2006). Insomnia following hypocre-
tin2-saporin lesions of the substantia 
nigra. Neuroscience 137, 29–36.
Gerashchenko, D., Chou, T. C., Blanco-
Centurion, C. A., Saper, C. B., and 
Shiromani, P. J. (2004). Effects of 
lesions of the histaminergic tubero-
mammillary nucleus on spontaneous 
sleep in rats. Sleep 27, 1275–1281.
Gessa, G. L., Porceddu, M. L., Collu, M., 
Mereu, G., Serra, M., Ongini, E., and 
Biggio, G. (1985). Sedation and sleep 
induced by high doses of apomor-
phine after blockade of D-1 receptors 
by SCH 23390. Eur. J. Pharmacol. 109, 
269–274.
Gjerstad, M. D., Wentzel-Larsen, T., 
Aarsland, D., and Larsen, J. P. (2007). 
Frontiers in Neuroanatomy www.frontiersin.org November 2010 | Volume 4 | Article 145 | 10
Vetrivelan et al. Basal ganglia and sleep
hypoactive, adipsic, and aphagic. Cell 
83, 1197–1209.
Conflict of Interest Statement: The 
authors declare that the research was con-
ducted in the absence of any commercial or 
financial relationships that could be con-
strued as a potential conflict of interest.
Received: 30 June 2010; accepted: 20 
October 2010; published online: 23 
November 2010.
Citation: Vetrivelan R, Qiu M-H, 
Chang C and Lu J (2010) Role of basal 
ganglia in sleep–wake regulation: neu-
ral circuitry and clinical significance. 
Front. Neuroanat. 4:145. doi: 10.3389/
fnana.2010.00145
Copyright © 2010 Vetrivelan, Qiu, Chang 
and Lu. This is an open-access article subject 
to an exclusive license agreement between 
the authors and the Frontiers Research 
Foundation, which permits unrestricted 
use, distribution, and reproduction in any 
medium, provided the original authors and 
source are credited.
Wichmann, T., and DeLong, M. R. 
(2006). “Neurotransmitters and 
 disorders of the basal ganglia,” in 
Basic Neurochemistry Molecular, 
Cellular, and Medical Aspects, Vol. 1, 
eds G. J. Siegel, R. W. Albers, S. Brady, 
and D. Price (Burlington: Elsevier), 
761–776.
Wilson, J. S., Hull, C. D., and Buchwald, 
N. A. (1983). Intracellular studies of 
the convergence of sensory input on 
caudate neurons of cat. Brain Res. 270, 
197–208.
Wisor, J. P., Nishino, S., Sora, I., Uhl, G. H., 
Mignot, E., and Edgar, D. M. (2001). 
Dopaminergic role in stimulant-
induced wakefulness. J. Neurosci. 21, 
1787–1794.
Xu, T. X., and Yao, W. D. (2010). D1 and 
D2 dopamine receptors in separate 
circuits cooperate to drive associative 
long-term potentiation in the prefron-
tal cortex. Proc. Natl. Acad. Sci. U.S.A. 
107, 16366–16371.
Zhou, Q. Y., and Palmiter, R. D. (1995). 
Dopamine-deficient mice are severely 
Soikkeli, R., Partanen, J., Soininen, H., 
Pääkkönen, A., and Riekkinen P, S. r. 
(1991). Slowing of EEG in Parkinson’s 
disease. Electroencephalogr. Clin, 
Neurophysiol. 79, 159–165.
Steininger, T. L., Rye, D. B., and Wainer, 
B. H. (1992). Afferent projections 
to the cholinergic pedunculopon-
tine  tegmental nucleus and adjacent 
 midbrain extrapyramidal area in 
the albino rat. I. Retrograde trac-
ing studies. J. Comp. Neurol. 321, 
515–543.
Urbain, N., Gervasoni, D., Souliere, F., 
Lobo, L., Rentero, N., Windels, F., 
Astier, B., Savasta, M., Fort, P., Renaud, 
B., Luppi, P. H., and Chouvet, G. 
(2000). Unrelated course of subtha-
lamic nucleus and globus pallidus 
neuronal activities across vigilance 
states in the rat. Eur. J. Neurosci. 12, 
3361–3374.
Vanderwolf, C. H., and Stewart, D. J. 
(1988). Thalamic control of neocor-
tical activation: a critical re-evaluation. 
Brain Res. Bull. 20, 529–538.
activity in neocortex. Nat. Neurosci. 
3, 1027–1034.
Saper, C. B. (1984). Organization of cer-
ebral cortical afferent systems in the 
rat. II. Magnocellular basal nucleus. J. 
Comp. Neurol. 222, 313–342.
Sarter, M., and Bruno, J. P. (2002). The 
neglected constituent of the basal 
forebrain corticopetal projection sys-
tem: GABAergic projections. Eur. J. 
Neurosci. 15, 1867–1873.
Schafer, D., and Greulich, W. (2000). 
Effects of parkinsonian medication 
on sleep. J. Neurol. 247, 24–27.
Schroeder, U., Kreutz, M. R., Schroeder, H., 
and Sabel, B. A. (1997). Amphetamine 
induces hypermotility in MPTP-
lesioned mice. Pharmacol. Biochem. 
Behav. 56, 281–285.
Serizawa, K., Kamei, S., Morita, A., Hara, M., 
Mizutani, T., Yoshihashi, H., Yamaguchi, 
M., Takeshita, J., and Hirayanagi, K. 
(2008). Comparison of quantitative 
EEGs between Parkinson disease and 
age-adjusted normal controls. J. Clin. 
Neurophysiol. 25, 361–366.
